Haematological malignancies increase the risk of infection, but the pathology of these diseases and their treatments complicate the management of infections. Some of the infections are vaccine preventable, and therefore this is an approach that should be considered. However, it is not straightforward since the approach differs because of the nature of the malignancy, treatment, infection, and vaccine. A particular limitation of vaccination in these patients is the use of live-attenuated vaccines (LAVs) because of the risk of vaccine-induced disease in the context of immunocompromise.